The company said, “Based on OptimizeRx’s results for the first nine months of 2023 and its recent acquisition, the Company is updating its full year financial outlook for 2023. Revenues for 2023 are now expected to be between $68 million and $70 million and we expect our adjusted EBITDA to come in between $3 million and $4 million.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OPRX:
- OptimizeRx Reports Third Quarter 2023 Financial Results
- Is OPRX a Buy, Before Earnings?
- OptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ET
- OptimizeRx announces completion of Medicx acquisition
- OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers